Investment Rating - The report maintains a "Buy" rating for the company [1][4][7] Core Views - The company has shown stable growth in its profitability, with a notable increase in net profit for the first half of 2024 [2][3] - The automotive components business is experiencing significant growth, and there is optimism regarding the potential orders for pre-plated nickel [2][3] - The company is expected to benefit from the increasing demand for large cylindrical batteries, with plans to secure mass production orders by the end of the year [3][4] Financial Summary - The company achieved a revenue of 20.59 billion yuan in the first half of 2024, a year-on-year increase of 0.63%, and a net profit of 2.13 billion yuan, up 10.61% year-on-year [2][3] - For the second quarter, revenue reached 11.83 billion yuan, representing a 3.88% year-on-year increase and a 35.13% quarter-on-quarter increase [2][3] - The projected net profits for 2024, 2025, and 2026 are 4.39 billion yuan, 4.57 billion yuan, and 4.77 billion yuan respectively, with corresponding P/E ratios of 12.39, 11.90, and 11.41 [2][4][5]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company reported a revenue of 2.264 billion yuan in the first half of 2024, representing a year-on-year growth of 1.32%, and a net profit attributable to shareholders of 69 million yuan, up 155.44% year-on-year [2][4] - The lithium battery anode segment saw a significant increase in shipment volume, with a growth rate exceeding 50% [2] - The company is actively expanding its magnetic and electric equipment business, focusing on high-end electromagnetic metallurgy equipment and international steel markets [2] Financial Summary - The company’s main revenue projections are as follows: 5.373 billion yuan for 2024, 6.889 billion yuan for 2025, and 8.859 billion yuan for 2026 [4] - The projected net profit attributable to shareholders is 262 million yuan for 2024, 424 million yuan for 2025, and 622 million yuan for 2026 [4] - The earnings per share (EPS) are expected to be 0.38 yuan for 2024, 0.62 yuan for 2025, and 0.91 yuan for 2026 [4] - The company’s price-to-earnings (P/E) ratio is projected to be 20.77 for 2024, 12.86 for 2025, and 8.76 for 2026 [4] Operational Highlights - In Q2 2024, the company achieved a revenue of 1.198 billion yuan, a year-on-year increase of 0.39% and a quarter-on-quarter increase of 12.40% [2] - The gross margin and net margin for Q2 were reported at 19.78% and 6.85%, respectively, showing significant improvement [2] - The company has obtained 12 invention patents and has 103 patents under application [2]

| --- | --- | |-------------------------------|-----------------| | | | | 2024 年 09 月 02 日 | | | 评级 | 买入 | | 交易数据 | 评级变动 首次 | | 当前价格（元） | 5.30 | | 52 周价格区间（元） | 3.43-8.07 | | 总市值（百万） | 3115.20 | | 流通市值（百万） | 2441.90 | | 总股本（万股） | 58777.10 | | 流通股（万股） | 46073.60 | 涨跌幅比较 | --- | --- | --- | --- | |------------------------|----------|---------|---------| | | | | | | 60% 40% 20% 0% -20% | 九洲集团 | 电力 | | | -40% 2023/09 2023/12 | 2024/03 | 2024/06 | 2024/09 | | % | 1M | 3M | 12M | | 九洲集团 | 8.38 | -28.28 | -5.19 | ...

证券研究报告 公司点评 华泰证券(601688.SH) 非银金融｜ 证券Ⅱ 降杠杆收缩资产负债表，自营、投行、经纪拖累业绩 2024 年 09 月 02 日 评级 买入 | --- | --- | |-----------------------|-------------| | 当前价格（元） | 12.43 | | 52 周价格区间（元） | 11.88-16.80 | | 总市值（百万） | 104318.57 | | 流通市值（百万） | 90668.54 | | 总股本（万股） | 902938.50 | | 流通股（万股） | 901337.70 | 涨跌幅比较 华泰证券 证券Ⅱ -27% -17% -7% 3% 13% 2023-09 2023-12 2024-03 2024-06 2024-09 | --- | --- | --- | --- | |----------|-------|-------|--------| | % | 1M | 3M | 12M | | 华泰证券 | -3.27 | -5.48 | -20.98 | | 证券Ⅱ | -5.86 | -6.71 | -19.14 ...

证券研究报告 2024 年 09 月 02 日 评级 增持 | --- | --- | |-----------------------|-------------| | 评级变动 交易数据 | 维持 | | 当前价格（元） | 20.93 | | 52 周价格区间（元） | 17.74-34.66 | | 总市值（百万） | 9348.34 | | 流通市值（百万） | 9253.30 | | 总股本（万股） | 44664.80 | | 流通股（万股） | 44210.80 | | | | 涨跌幅比较 -34% -14% 6% 26% 46% 2023-09 2023-12 2024-03 2024-06 博众精工 自动化设备 | --- | --- | --- | --- | |------------|-------|--------|--------| | % | 1M | 3M | 12M | | 博众精工 | -1.88 | 6.62 | -22.02 | | 自动化设备 | 0.33 | -15.01 | -27.13 | 袁玮志 分析师 执业证书编号:S0530522050002 yuanw ...

2024 年 09 月 02 日 评级 买入 | --- | --- | |------------------------------------|--------------| | 评级变动 交易数据 \n当前价格（元） | 维持 \n10.26 | | 52 周价格区间（元） | 10.22-47.44 | | 总市值（百万） | 5609.60 | | 流通市值（百万） | 5310.62 | | 总股本（万股） | 54674.40 | | 流通股（万股） | 51760.40 | 涨跌幅比较 | --- | --- | --- | --- | |-------------------------------------|-----------------|----------|---------| | | | | | | | | | | | 16% | 高测股份 | 光伏设备 | | | -4% -24% -44% | | | | | -64% 2023-09 2023-12 | 2024-03 | 2024-06 | 2024-09 | | % | 1M | 3M | 12M | | 高测股份 ...

Investment Rating - The report assigns a "Buy" rating to Tigermed Consulting (300347 SZ) with a target price range of 49 10-57 33 yuan per share [1][8] Core Views - Tigermed's Q2 2024 performance showed sequential improvement with revenue of 1 698 billion yuan (-10 92% YoY +2 28% QoQ) and adjusted net profit of 337 million yuan (-18 19% YoY +11 29% QoQ) [5] - The company's new order intake in H1 2024 grew well benefiting from increased demand from multinational pharmaceutical companies in China and overseas clinical needs from Chinese pharmaceutical and biotech companies [8] - Tigermed's global clinical service capabilities continue to strengthen with 263 overseas projects ongoing as of June 2024 including 55 multi-regional clinical trials (MRCT) [7] Business Performance - In H1 2024 Tigermed achieved revenue of 3 358 billion yuan (-9 50% YoY) and adjusted net profit of 640 million yuan (-19 30% YoY) [5] - Clinical trial technical services revenue declined 22 17% YoY to 1 637 billion yuan due to reduced average order prices and the absence of certain vaccine project revenues from the previous year [6] - Clinical trial related services and laboratory services revenue grew 5 84% YoY to 1 659 billion yuan driven by strong demand and improved efficiency in site management services [6] International Expansion - Overseas revenue in H1 2024 was 1 474 billion yuan (-8 58% YoY) but showed growth after excluding specific vaccine project revenues from the previous year [6] - The company's overseas workforce reached 1 722 employees as of June 2024 with significant growth in North America (+10 45% YoY) and EMEA (+23 68% YoY) [6] - Tigermed completed the acquisition of Japan's Medical Edge Co Ltd in July 2024 strengthening its data management and clinical data information system services in Japan and the Asia-Pacific region [7] Financial Projections - Revenue is forecasted to grow from 7 298 billion yuan in 2024E to 9 881 billion yuan in 2026E [4] - Net profit attributable to shareholders is expected to increase from 1 248 billion yuan in 2024E to 2 542 billion yuan in 2026E [4] - EPS is projected to rise from 1 44 yuan in 2024E to 2 94 yuan in 2026E [4] Valuation - The report values Tigermed's investment business at 14 015 billion yuan based on the book value of its financial assets [8] - The clinical CRO business is valued at 28 460-35 575 billion yuan based on a 2024E PE multiple of 20-25x [8] - The combined valuation suggests a fair market capitalization range of 42 475-49 590 billion yuan for 2024 [8]

公司点评 新坐标（603040.SH） 证券研究报告 2024 年 09 月 02 日 评级 买入 | --- | --- | |-----------------------|-------------------| | 评级变动 交易数据 | 维持 | | 当前价格（元） | 19 . 03 | | 52 周价格区间（元） | 16 . 71 - 28 . 55 | | 总市值（百万） | 2571 . 11 | | 流通市值（百万） | 2559 . 37 | | 总股本（万股） | 13510 . 80 | | 流通股（万股） | 13449 . 20 | | | | 涨跌幅比较 | --- | --- | --- | --- | |------------------------|---------|------------|---------| | | | | | | 29% | 新坐标 | 汽车零部件 | | | 9% | | | | | -11% | | | | | | | | | | -31% 2023-09 2023-12 | 2024-03 | 2024-06 | 2024-09 | | ...

Investment Rating - The report assigns a "Buy" rating to the company, indicating a strong potential for investment returns exceeding the market index by over 15% [5][7]. Core Insights - The company reported a significant increase in revenue and net profit for the first half of 2024, with revenue reaching 6.622 billion yuan, a year-on-year growth of 62.19%, and net profit at 1.226 billion yuan, up 63.15% [3][4]. - The company's gross margin improved to 31.62%, an increase of 5.2 percentage points year-on-year, while the net profit margin was 18.53%, up 0.12 percentage points [3][4]. - The company has a robust order backlog, with contract liabilities amounting to 18.452 billion yuan, a 56% increase year-on-year, and inventory at 21.637 billion yuan, up 74% [3][4]. Financial Projections - The company is projected to achieve revenues of 14.325 billion yuan in 2024, 18.708 billion yuan in 2025, and 20.489 billion yuan in 2026, with corresponding net profits of 2.521 billion yuan, 3.368 billion yuan, and 3.873 billion yuan respectively [5][6]. - Earnings per share (EPS) are expected to rise from 7.24 yuan in 2024 to 11.12 yuan in 2026, reflecting strong growth potential [5][6]. - The price-to-earnings (P/E) ratio is projected to decrease significantly from 6.33 in 2024 to 4.12 in 2026, indicating an attractive valuation [5][6]. Market Position and Strategy - The company is positioned as a leader in the photovoltaic equipment sector, benefiting from the expansion of TOPCon production capacity and the replacement of older production lines [3][4]. - The company is actively pursuing a platform-based strategy to enhance its resilience against market fluctuations, focusing on advancements in TOPCon, HJT, and perovskite technologies [4][5]. - The company has successfully developed and delivered new semiconductor and lithium battery equipment, indicating diversification and growth in related sectors [5].

2024 年 08 月 29 日 评级 买入 | --- | --- | |-----------------------|-------------| | 当前价格（元） | 13.65 | | 52 周价格区间（元） | 13.58-33.36 | | 总市值（百万） | 26192.00 | | 流通市值（百万） | 18905.47 | | 总股本（万股） | 191882.40 | | 流通股（万股） | 138501.60 | 涨跌幅比较 天赐材料 电池 -58% -38% -18% 2% 22% 2023-08 2023-11 2024-02 2024-05 % 1M 3M 12M 杨鑫 分析师 执业证书编号:S0530524050001 yangxin13@hnchasing.com 相关报告 天赐材料 -11.59 -30.57 -57.61 电池 -5.80 -15.33 -32.44 1 天赐材料（002709.SZ）公司点评：与电池龙 头签订供货协议，市占率有望进一步提升 2024-06-18 证券研究报告 公司点评 天赐材料(002709.SZ) 电力设备｜ 电池 电解液出货量持续增 ...